Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Polyneuropathy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 

Hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy, previously known as familial amyloidotic polyneuropathy, is a rare genetic disorder caused by a mutation in the transthyretin (TTR) gene, which results in the production of abnormal TTR proteins that form amyloid fibrils. The disease is characterized by gradual and progressive degeneration of the autonomic and sensory-motor nervous systems and can be fatal. The symptoms of hATTR amyloidosis with polyneuropathy involve damage to the peripheral and autonomic nervous systems. Peripheral neuropathy usually begins with unusual sensations in the lower limbs, such as numbness, tingling, or burning. Autonomic neuropathy occurs when nerves that control vital functions, such as blood pressure, heart rate, sweating, bladder emptying, and digestion, are damaged. The sensory-motor polyneuropathy in hATTR amyloidosis with polyneuropathy progresses through three stages. In the initial stage, patients typically experience mild sensory symptoms in the lower limbs, but their ability to walk unassisted is preserved. In the second stage, patients require assistance for walking due to the progressive weakness of the lower limb muscles. In the final stage, sensory symptoms are severe, and patients experience flaccid paralysis or severe weakness of all limbs, resulting in the need for a wheelchair or bedridden state. The polyneuropathy disability (PND) score is commonly used to stage the degree of sensory-motor impairment in clinical practice. Patients with PND 0 have no impairment, while those with PND I have sensory disturbances but maintain the ability to walk. Patients with PND II have impaired walking ability but can still walk without a cane or crutch. Patients with PND IIIa require a single cane or crutch, PND IIIb requires two canes or crutches, and PND IV is characterized by wheelchair dependence or bedridden.

  • The global prevalence of hereditary transthyretin-mediated amyloid polyneuropathy was estimated at 38,000 individuals.

 

Thelansis’s “Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Polyneuropathy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Polyneuropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Polyneuropathy across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Polyneuropathy Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Polyneuropathy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more